dosing

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

October 24, 2025 07:02 ET  | Source: Kura Oncology, Inc. - Milestone triggered by dosing of first patient in frontline…

2 weeks ago

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing…

2 weeks ago

LEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in China

September 28, 2025 19:30 ET  | Source: Biogen Inc. TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai…

1 month ago

Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients

August 21, 2025 01:30 ET  | Source: NICOX SA Press Release Nicox Announces Positive Results from the NCX 470 Phase…

3 months ago

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing…

4 months ago

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for…

5 months ago

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,…

5 months ago